Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)
ID: 357087Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357087

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-170.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development," aimed at supporting the development and validation of digital health technology-driven biomarkers and clinical outcome assessments for use in clinical trials. This initiative seeks to enhance the standardization of remote assessments and address unmet clinical needs across multiple diseases, requiring applicants to engage with non-profit patient advocacy organizations and evaluate technologies in diverse populations. The funding mechanism consists of two phases: the UG3 phase focuses on assessing the technical performance of proposed technologies, while the UH3 phase supports longitudinal clinical studies for validation. Interested applicants can find more information and application details at the NIH grants website, with a submission deadline of June 22, 2026, and no cost-sharing or matching requirement.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-170-Full-Announcement.html
    PAR-25-170.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a funding opportunity titled "Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development". This initiative seeks to develop and validate digital health technology-driven biomarkers and clinical outcome assessments for remote monitoring in clinical trials. The program supports research across multiple diseases, emphasizing collaboration with individuals with lived experience and patient advocacy groups. The funding is built around a two-phase mechanism: the first phase (UG3) focuses on evaluating the technical performance of proposed digital health technologies, while the second phase (UH3) supports longitudinal clinical studies to validate the technologies. Key goals include enhancing the standardization of remote assessments and meeting unmet clinical needs in varied disease areas. Eligible applicants include various educational institutions, for-profit and non-profit organizations, and should adhere to specific application and submission protocols. Emphasizing community engagement and a clear strategic plan, the program mandates proper data management and sharing strategies. This funding opportunity aligns with NIH's commitment to advancing digital health initiatives for improved patient outcomes and clinical trial efficiency.
    Similar Opportunities
    Laboratories to Optimize Digital Health (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Laboratories to Optimize Digital Health" grant, aimed at enhancing the reach and effectiveness of digital mental health interventions. This initiative focuses on innovative research projects that leverage established digital health platforms to conduct clinical trials, ultimately seeking to address health disparities and improve mental health outcomes. The funding opportunity encourages collaboration and the development of scalable, technology-driven solutions, with no budget limits and a maximum project period of four years. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with applications due by March 5, 2025.
    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at advancing the development of Digital Therapeutics (DTx) for treating Substance Use Disorders (SUDs). This initiative seeks to support the creation of safe and effective clinical-grade digital platforms that can deliver therapeutic treatments, particularly for conditions that currently lack FDA-approved medications. The funding mechanism involves a two-phase cooperative agreement, with the UG3 phase focusing on initial milestones and design testing for up to two years, followed by the UH3 phase, which can extend for an additional three years upon successful completion of the UG3 phase. Eligible applicants include a diverse range of organizations, such as educational institutions, tribal governments, and community-based organizations. The application process opens on February 26, 2024, with multiple deadlines extending through late 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)" aimed at developing medical technologies that address health disparities among underserved populations in the U.S. This initiative encourages grant applications focused on creating effective, affordable, culturally acceptable, and accessible medical solutions, including devices, imaging systems, and telehealth innovations, while emphasizing the importance of formal collaborations with healthcare organizations serving these populations. The NIH plans to allocate approximately $2.4 million for this initiative, with an award ceiling of $500,000 per project, and expects to fund 3-4 awards over a project duration of up to four years. Interested applicants must submit their proposals by May 2, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Laboratories to Optimize Digital Health (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Laboratories to Optimize Digital Health" initiative, aimed at enhancing the reach and effectiveness of digital mental health interventions through innovative research projects. This funding opportunity focuses on developing digital health test beds to optimize existing evidence-based interventions, particularly targeting vulnerable populations and addressing health disparities. The initiative supports clinical trials and encourages collaboration between software developers and researchers to understand the mechanisms of action behind these interventions. Applications open on January 5, 2025, with multiple due dates leading to awards expected to begin in July 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the clinical validation of candidate biomarkers for neurological and neuromuscular disorders through the U44 Cooperative Agreement mechanism. This initiative aims to rigorously validate biomarkers that have already been identified and for which detection methods have been developed, ensuring compliance with FDA guidelines to establish their clinical sensitivity and specificity. This program is crucial for advancing therapeutic development in the field of brain health, with funding potentially reaching $700,000 for Phase I and $1.5 million for Phase II projects. Interested applicants must adhere to specific submission guidelines and deadlines, with the application closing on June 22, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-096.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)." This initiative aims to support the clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders, focusing on establishing their clinical sensitivity and specificity in accordance with FDA guidelines. The program is particularly significant as it seeks to enhance public health outcomes by facilitating the implementation of validated biomarkers in clinical settings, thereby addressing critical healthcare needs in these areas. Interested applicants should note that the application period opens on January 21, 2025, and closes on June 22, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-055.html.
    Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)" under Funding Opportunity Number PAR-24-097. This initiative aims to clinically validate candidate biomarkers for neurological diseases, focusing on establishing their clinical sensitivity and specificity, provided that preliminary conditions such as detection method development are met. The program emphasizes the importance of multidisciplinary collaborations and requires applicants to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams. Interested applicants must submit their proposals by February 22, 2024, with project durations capped at five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-097.html.
    Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Novel Assays to Address Translational Gaps in Treatment Development" initiative, aimed at advancing neurophysiological measures that can serve as assays for drug and device therapies in mental health research. This funding opportunity encourages collaborative partnerships among neuroscientists to optimize in vivo testing in both preclinical species and humans, with a focus on bridging the gap between preclinical and clinical measures to enhance therapeutic outcomes for mental disorders. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with key deadlines including an application due date of January 21, 2025, and a funding expiration on June 21, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.